| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000064927 |
| P698 | PubMed publication ID | 12145453 |
| P50 | author | John T. O'Brien | Q37830687 |
| Michael J. Firbank | Q45836903 | ||
| Roger Harrison | Q57235296 | ||
| P2093 | author name string | O'Brien JT | |
| Harrison RM | |||
| Firbank MJ | |||
| P433 | issue | 2 | |
| P921 | main subject | spectroscopy | Q483666 |
| Parkinson's disease | Q11085 | ||
| dementia | Q83030 | ||
| P304 | page(s) | 64-76 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Dementia and Geriatric Cognitive Disorders | Q15749436 |
| P1476 | title | A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease | |
| P478 | volume | 14 |
| Q58885392 | A metabonomic approach to evaluate COPD in a model of cigarette smoke exposure in mice |
| Q33825847 | Aging masks detection of radiation-induced brain injury |
| Q37191378 | Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics. |
| Q48160114 | Basal ganglia cellular pathology in multiple system atrophy, progressive supranuclear palsy and Parkinson disease. Can quantitative magnetic resonance spectroscopic imaging make the difference? |
| Q35237100 | Biological markers for early detection and pharmacological treatment of Alzheimer's disease |
| Q48488601 | Brain anatomy and ageing in non-demented adults with Down's syndrome: an in vivo MRI study |
| Q37010486 | Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia |
| Q40011287 | Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation |
| Q48670459 | Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild Alzheimer's disease |
| Q34951012 | Distinct Neurochemical Profiles of Spinocerebellar Ataxias 1, 2, 6, and Cerebellar Multiple System Atrophy |
| Q51972858 | Executive function is associated with brain proton magnetic resonance spectroscopy in amnestic mild cognitive impairment. |
| Q35863417 | Functional imaging in Parkinson's disease and dementia with Lewy bodies |
| Q34554452 | Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts |
| Q33427621 | In vivo 1H-magnetic resonance spectroscopy can detect metabolic changes in APP/PS1 mice after donepezil treatment |
| Q28235219 | KCNQ1, KCNE2, and Na+-coupled solute transporters form reciprocally regulating complexes that affect neuronal excitability |
| Q37082107 | MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice |
| Q39220904 | Magnetic resonance imaging for the diagnosis of Parkinson's disease |
| Q26865688 | Magnetic resonance imaging markers for early diagnosis of Parkinson's disease |
| Q31049661 | Magnetic resonance imaging of Alzheimer's disease |
| Q36864333 | Magnetic resonance imaging of myelin |
| Q34287154 | Magnetic resonance imaging of the substantia nigra in Parkinson's disease |
| Q35623532 | Magnetic resonance spectroscopy and neurocognitive dysfunction in obstructive sleep apnea before and after CPAP treatment |
| Q30858994 | Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease? |
| Q46844307 | Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse |
| Q37289506 | Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection |
| Q37583283 | Moderate relationships between NAA and cognitive ability in healthy adults: implications for cognitive spectroscopy |
| Q47950496 | NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy |
| Q30836861 | Neuroimaging characteristics of dementia with Lewy bodies. |
| Q83316032 | Neuroimaging in Parkinson's disease |
| Q39060890 | Neurometabolic profiles of the substantia nigra and striatum of MPTP-intoxicated common marmosets: An in vivo proton MRS study at 9.4 T. |
| Q97553814 | Non-invasive characterization of amyotrophic lateral sclerosis in a hTDP-43A315T mouse model: A PET-MR study |
| Q43232740 | Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease |
| Q64923944 | Plasma metabolic profiling analysis of neurotoxicity induced by oxaliplatin using metabonomics and multivariate data analysis. |
| Q47663712 | Potential clinical utility of multiple system atrophy biomarkers |
| Q41657488 | Progressive brain metabolic changes under deep brain stimulation of subthalamic nucleus in parkinsonian rats |
| Q33462288 | Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment |
| Q38405355 | Proton magnetic resonance spectroscopy in frontotemporal dementia. |
| Q45269942 | Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease. |
| Q35677156 | Scyllo-inositol in normal aging human brain: 1H magnetic resonance spectroscopy study at 4 Tesla |
| Q37097465 | Single voxel magnetic resonance spectroscopy at 3 Tesla in a memory disorders clinic: early right hippocampal NAA/Cr loss in mildly impaired subjects |
| Q41624442 | T1rho (T1ρ) MR imaging in Alzheimer's disease and Parkinson's disease with and without dementia |
| Q38659608 | The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial. |
| Q35781558 | Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). |
Search more.